-
公开(公告)号：US20250073219A1
公开(公告)日：2025-03-06
申请号：US18567452
申请日：2022-06-10
Applicant: NANEXA AB
Inventor： Joel HELLRUP , Jonas FRANSSON , Mårten ROOTH , Anders JOHANSSON , David WESTBERG , Erik LINDAHL
IPC: A61K31/454 , A61K9/50
Abstract: The invention relates to a plurality of coated particles containing a solid core containing one of the compounds lenalidomide and pomalidomide, or a pharmaceutically acceptable salt thereof. The core has a mean diameter of the between 0.1 pm and 50 pm. The core is a coated by a coating surrounding, enclosing and/or encapsulating the core. The coating contains a mixed oxide selected from the group consisting of iron oxide, zinc oxide, silicon oxide, titanium oxide, and aluminium oxide.
-
公开(公告)号：US20240277624A1
公开(公告)日：2024-08-22
申请号：US18568363
申请日：2022-06-10
Applicant: NANEXA AB
Inventor： Anders JOHANSSON , Mårten ROOTH , Erik LINDAHL , Joel HELLRUP , Jonas FRANSSON , David WESTBERG , Otto SKOLLING
CPC classification number: A61K9/5073 , A61K9/0019 , A61K9/10 , A61K9/501 , A61K9/5115 , C23C16/407 , C23C16/4417 , C23C16/45555 , A61K38/00
Abstract: There is provided a pharmaceutical formulation that is useful in delivering a biologic active drug in a high dose, comprising a plurality of particles suspended in an aqueous carrier system, which particles: pharmaceutical formulation, comprising a plurality of particles suspended in a carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 pm; and (b) comprise solid cores comprising a biologic active drug, coated, at least in part, by a coating of inorganic material, and wherein the formulation comprises a concentration of said biologic active drug of at least 10 mg/ml. Preferred biologic active drug include immunoglobulins, monoclonal antibodies, antibody mimetics, cytokines and cytokine antagonists, and human peptide hormones.
-
Search Results
2
records
(took 0.025 seconds)
